Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 12Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1

Interventions

pembrolizumab 2enfortumab vedotin 2Nivolumab 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1relatlimab 1erdafitinib 1avelumab 1Vinblastine 1Specimen Handling 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muscle Invasive Bladder Urothelial Carcinoma × Immunoglobulin G × Genitourinary × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡